Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system Z Culig, J Hoffmann, M Erdel, IE Eder, A Hobisch, A Hittmair, G Bartsch, ... British journal of cancer 81 (2), 242-251, 1999 | 491 | 1999 |
Establishment of patient-derived non–small cell lung cancer xenografts as models for the identification of predictive biomarkers I Fichtner, J Rolff, R Soong, J Hoffmann, S Hammer, A Sommer, M Becker, ... Clinical cancer research 14 (20), 6456-6468, 2008 | 355 | 2008 |
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors M Schütte, T Risch, N Abdavi-Azar, K Boehnke, D Schumacher, M Keil, ... Nature communications 8 (1), 14262, 2017 | 308 | 2017 |
Total synthesis and antitumor activity of ZK‐EPO: the first fully synthetic epothilone in clinical development U Klar, B Buchmann, W Schwede, W Skuballa, J Hoffmann, RB Lichtner Angewandte Chemie 118 (47), 8110-8116, 2006 | 166 | 2006 |
Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor IE Eder, J Hoffmann, H Rogatsch, G Schäfer, D Zopf, G Bartsch, H Klocker Cancer gene therapy 9 (2), 117-125, 2002 | 137 | 2002 |
Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist U Fuhrmann, H Hess-Stumpp, A Cleve, G Neef, W Schwede, J Hoffmann, ... Journal of medicinal chemistry 43 (26), 5010-5016, 2000 | 136 | 2000 |
Regorafenib (BAY 73‐4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer R Schmieder, J Hoffmann, M Becker, A Bhargava, T Müller, N Kahmann, ... International journal of cancer 135 (6), 1487-1496, 2014 | 132 | 2014 |
Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone J Hoffmann, I Vitale, B Buchmann, L Galluzzi, W Schwede, L Senovilla, ... Cancer research 68 (13), 5301-5308, 2008 | 124 | 2008 |
Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. M Schirner, J Hoffmann, A Menrad, MR Schneider Clinical cancer research: an official journal of the American Association …, 1998 | 120 | 1998 |
Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer J Hoffmann, R Bohlmann, N Heinrich, H Hofmeister, J Kroll, H Künzer, ... Journal of the National Cancer Institute 96 (3), 210-218, 2004 | 112 | 2004 |
A Highly Sensitive Model for Quantification of in Vivo Tumor Angiogenesis Induced by Alginate-encapsulated Tumor Cells J Hoffmann, M Schirner, A Menrad, MR Schneider Cancer research 57 (17), 3847-3851, 1997 | 94 | 1997 |
Sagopilone crosses the blood–brain barrier in vivo to inhibit brain tumor growth and metastases J Hoffmann, I Fichtner, M Lemm, P Lienau, H Hess-Stumpp, A Rotgeri, ... Neuro-oncology 11 (2), 158-166, 2009 | 92 | 2009 |
Cloning and heterologous expression of the aranciamycin biosynthetic gene cluster revealed a new flexible glycosyltransferase A Luzhetskyy, A Mayer, J Hoffmann, S Pelzer, M Holzenkämper, B Schmitt, ... ChemBioChem 8 (6), 599-602, 2007 | 74 | 2007 |
Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures D Schumacher, G Andrieux, K Boehnke, M Keil, A Silvestri, M Silvestrov, ... PLoS Genetics 15 (3), e1008076, 2019 | 73 | 2019 |
A comprehensively characterized large panel of head and neck cancer patient‐derived xenografts identifies the m TOR inhibitor everolimus as potential new treatment option K Klinghammer, JD Raguse, T Plath, AE Albers, K Joehrens, A Zakarneh, ... International journal of cancer 136 (12), 2940-2948, 2015 | 64 | 2015 |
Studies on the development of resistance to the pure antiestrogen Faslodex™ in three human breast cancer cell lines A Sommer, J Hoffmann, RB Lichtner, MR Schneider, K Parczyk The Journal of steroid biochemistry and molecular biology 85 (1), 33-47, 2003 | 59 | 2003 |
Choosing wisely–Preclinical test models in the era of precision medicine K Klinghammer, W Walther, J Hoffmann Cancer treatment reviews 55, 36-45, 2017 | 54 | 2017 |
Steroidhormone receptors as targets for the therapy of breast and prostate cancer—recent advances, mechanisms of resistance, and new approaches J Hoffmann, A Sommer The Journal of steroid biochemistry and molecular biology 93 (2-5), 191-200, 2005 | 53 | 2005 |
Subcellular distribution of epothilones in human tumor cells RB Lichtner, A Rotgeri, T Bunte, B Buchmann, J Hoffmann, W Schwede, ... Proceedings of the National Academy of Sciences 98 (20), 11743-11748, 2001 | 52 | 2001 |
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets C Swanton, JM Larkin, M Gerlinger, AC Eklund, M Howell, G Stamp, ... Genome medicine 2, 1-10, 2010 | 48 | 2010 |